Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: HMP009
MIFTS: 43

Haemophilus Influenzae

Categories: Infectious diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Haemophilus Influenzae

About this section

MalaCards integrated aliases for Haemophilus Influenzae:

Name: Haemophilus Influenzae 52
H. Influenzae 52

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

ICD10 32 B96.3
Sources

Summaries for Haemophilus Influenzae

About this section
MalaCards based summary : Haemophilus Influenzae, also known as h. influenzae, is related to epiglottitis and bacterial meningitis. An important gene associated with Haemophilus Influenzae is LACTB (Lactamase Beta), and among its related pathways/superpathways are IL-17 Family Signaling Pathways and Salmonella infection (KEGG). The drugs Temocillin and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include testes, colon and lung, and related phenotype is homeostasis/metabolism.

Wikipedia : 74 Haemophilus influenzae (formerly called Pfeiffer's bacillus or Bacillus influenzae) is a Gram-negative,... more...

Sources

Related Diseases for Haemophilus Influenzae

About this section

Diseases related to Haemophilus Influenzae via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 578)
# Related Disease Score Top Affiliating Genes
1 epiglottitis 33.4 OMP LACTB
2 bacterial meningitis 32.4 TNF TLR2 LACTB CXCL8
3 meningitis 31.5 TNF TLR2 LACTB CXCL8
4 otitis media 31.4 TNF TLR2 LACTB CXCL8
5 septic arthritis 31.1 TNF TLR2 CXCL8
6 pneumonia 31.0 VTN TNF TLR2 LACTB CXCL8
7 bronchitis 30.9 TNF TLR2 LTF LACTB CXCL8
8 pericarditis 30.9 VTN TNF CXCL8
9 osteomyelitis 30.8 TNF TLR2 CXCL8
10 neisseria meningitidis infection 30.8 TLR2 OMP LACTB
11 bronchopneumonia 30.7 TNF CXCL8
12 bronchiectasis 30.7 TNF TLR2 CXCL8
13 lung abscess 30.7 TNF LACTB
14 measles 30.7 TNF TLR2 CXCL8
15 salpingitis 30.6 TNF TLR2
16 peritonitis 30.5 TNF TLR2 CXCL8
17 endophthalmitis 30.5 TNF TLR2 CXCL8
18 toxic shock syndrome 30.5 TNF TLR2 CXCL8
19 acute cystitis 30.5 TNF TLR2 CXCL8
20 endocarditis 30.5 TNF TLR2 LACTB CXCL8
21 urethritis 30.4 TNF TLR2 CXCL8
22 pharyngitis 30.4 TNF LACTB CXCL8
23 tonsillitis 30.3 TNF TLR2 LACTB CXCL8
24 meningococcal meningitis 30.3 TLR2 CFH
25 bacterial infectious disease 30.3 TNF TLR2 LTF CXCL8
26 bacterial pneumonia 30.2 TNF TLR2 LACTB CXCL8
27 vaginitis 30.2 TNF TLR2 CXCL8
28 streptococcus pneumonia 30.2 TNF TLR2 CXCL8
29 gastroenteritis 30.2 TNF LACTB CXCL8
30 middle ear disease 30.1 TNF TLR2 CXCL8
31 bacterial sepsis 30.1 TNF TLR2 CXCL8
32 aspiration pneumonitis 30.1 TNF CXCL8
33 pustulosis of palm and sole 30.1 TNF CXCL8
34 chlamydia 30.0 TNF TLR2 CXCL8
35 vaginal discharge 30.0 TNF CXCL8
36 common cold 30.0 TNF TLR2 CXCL8
37 bronchiolitis 30.0 TNF TLR2 CXCL8
38 cystic fibrosis 29.9 TNF TLR2 LTF CXCL8
39 preterm premature rupture of the membranes 29.9 TNF TLR2 CXCL8
40 endometritis 29.8 TNF TLR2 LACTB CXCL8
41 deficiency anemia 29.8 TNF TF LTF
42 chlamydia pneumonia 29.7 TNF TLR2 CXCL8
43 periodontitis 29.7 TNF TLR2 CXCL8
44 cervicitis 29.7 TNF TLR2 CXCL8
45 aphthous stomatitis 29.7 TNF TLR2 CXCL8
46 proteasome-associated autoinflammatory syndrome 1 29.6 TNF TLR2 CXCL8
47 chronic mucocutaneous candidiasis 29.6 TNF TLR2 CLEC7A
48 alcoholic hepatitis 29.6 TNF TLR2 CXCL8
49 food allergy 29.6 TNF TLR2 CXCL8
50 gout 29.6 TNF TLR2 CXCL8

Graphical network of the top 20 diseases related to Haemophilus Influenzae:



Diseases related to Haemophilus Influenzae
Sources

Symptoms & Phenotypes for Haemophilus Influenzae

About this section

MGI Mouse Phenotypes related to Haemophilus Influenzae:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.28 CFH CLEC7A LACTB LTF OMP TF
Sources

Drugs & Therapeutics for Haemophilus Influenzae

About this section

Drugs for Haemophilus Influenzae (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temocillin Approved, Investigational Phase 4 66148-78-5
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
5 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
7
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
8
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
9 Strawberry Approved Phase 4
10
Olodaterol Approved Phase 4 868049-49-4
11
Budesonide Approved Phase 4 51333-22-3 63006 5281004
12
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
13 Chlorine dioxide Investigational Phase 4 10049-04-4
14 Anti-Inflammatory Agents Phase 4
15 Methylprednisolone Acetate Phase 4
16 Antineoplastic Agents, Hormonal Phase 4
17 Antitoxins Phase 4
18 Aluminum phosphate Phase 4
19 Chlorhexidine gluconate Phase 4
20 Anti-Infective Agents, Local Phase 4
21 Disinfectants Phase 4
22 Micronutrients Phase 4
23 Trace Elements Phase 4
24 Parasympatholytics Phase 4
25 Cholinergic Agents Phase 4
26 Tiotropium Bromide Phase 4 136310-93-5
27 Cholinergic Antagonists Phase 4
28 Adrenergic beta-Agonists Phase 4
29 Hormones Phase 4
30
Salmeterol xinafoate Phase 4 94749-08-3 56801
31 Adrenergic Agents Phase 4
32 Formoterol Fumarate Phase 4
33 Hormone Antagonists Phase 4
34 Fluticasone-Salmeterol Drug Combination Phase 4
35 glucocorticoids Phase 4
36 Anticonvulsants Phase 4
37 Sympathomimetics Phase 4
38 Bromides Phase 4
39 Neurotransmitter Agents Phase 4
40 Adrenergic Agonists Phase 4
41
Gemifloxacin Approved, Investigational Phase 3 175463-14-6 5464436 9571107
42
Rabeprazole Approved, Investigational Phase 3 117976-89-3 5029
43
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
44
tannic acid Approved Phase 3 1401-55-4
45
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
46
Edetic Acid Approved, Vet_approved Phase 3 60-00-4, 62-33-9 6049
47
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
48
Pentetic acid Approved Phase 3 67-43-6
49
Deferiprone Approved Phase 3 30652-11-0 2972
50
Aluminum hydroxide Approved, Investigational Phase 3 21645-51-2

Interventional clinical trials:

(show top 50) (show all 265)
# Name Status NCT ID Phase Drugs
1 Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants Unknown status NCT00877357 Phase 4
2 Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study Unknown status NCT00545961 Phase 4 placebo;amoxicillin clavulanate acid
3 Temocillin Pharmacokinetics in Paediatrics Unknown status NCT02260102 Phase 4 Temocillin
4 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
5 Phase 4 Study of Haemophilus Influenzae Type b Vaccine in Different Injection Site Completed NCT01761136 Phase 4
6 The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine Completed NCT00197782 Phase 4
7 An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. Completed NCT00617812 Phase 4
8 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
9 Assess the Safety & Reactogenicity of GSK Biologicals Hib Vaccine Co-administered With Chinese Local DTPw Vaccine When Compared to Chinese Local DTPw Vaccine Administered Alone, in Healthy Infants at 3,4 & 5 Mths of Age Completed NCT00158795 Phase 4
10 A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. Completed NCT00674908 Phase 4
11 A Post Marketing Surveillance Study to Monitor the Reactogenicity and Safety of Vaxemâ„¢Hib When Administered According to the Prescribing Information in Korea Completed NCT01404962 Phase 4
12 A Demonstration Project for the Elimination of Haemophilus Influenzae Type B in Three Rural Alaska Native Villages Completed NCT00153556 Phase 4
13 Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections. Completed NCT01735084 Phase 4
14 A Randomized Clinical Trial on the Effect of a Chlorine Dioxide Spray on Dental Plaque and Respiratory Pathogens in Institutionalized Elders Completed NCT03533335 Phase 4
15 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACELâ„¢ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
16 A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age Completed NCT01357720 Phase 4
17 Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
18 Assessment of Long-term Antibody Persistence After a Booster Dose of GSK Biologicals' Hib & Meningococcal C Vaccine (Menitorixâ„¢) 811936 Given at 12-15 Months of Age to Subjects Primed With 3 Doses of Menitorixâ„¢ at 2, 3, 4 Months of Age Completed NCT00454987 Phase 4
19 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexaâ„¢) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
20 An Open-Label Multi-Center Study of Eculizumab in Children and Adolescents With a Diagnosis of Paroxysmal Nocturnal Hemoglobinuria Completed NCT00867932 Phase 4 Eculizumab
21 A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX_COMBO): Immunogenicity, Carriage and Otitis Media Outcomes Completed NCT01174849 Phase 4 Synflorix;Prevenar13;COMBO
22 Pneumonia in Children: Aetiology, Ideal Antibiotic Duration, Quality of Life Completed NCT02258763 Phase 4 Amoxicillin-Potassium Clavulanate Combination;Placebo
23 A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age Completed NCT01896596 Phase 4
24 Randomized, Controlled Clinical Trial of Day-care Based and Hospitalized Management of Severe and Very Severe Pneumonia, With Severe Malnutrition, With/Without Associated Co-morbidities in Children Completed NCT00968370 Phase 4
25 Efficacy of Antimicrobials in Young Children With Acute Otitis Media (AOM) Completed NCT00377260 Phase 4 amoxicillin-clavulanate;Placebo
26 A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children Completed NCT02385513 Phase 4
27 INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol Recruiting NCT03152149 Phase 4 Tiotropium & olodaterol;fluticasone furoate & vilanterol
28 Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study Active, not recruiting NCT02447718 Phase 4
29 Babies Born Early Antibody Response to Men B Vaccination: A Phase IV Multicentre Randomised Study to Evaluate the Primary and Booster Immune Responses in UK Preterm Infants Receiving Routine Immunisations and Incorporating a Three Dose Versus a Two Dose Schedule of 4CMenB (Bexsero®) for Primary Immunisation. Active, not recruiting NCT03125616 Phase 4
30 Investigating the Mechanism of Inhaled Corticosteroids Associated Pneumonia by Longitudinal Characterisation of the Airway Microbiome in Patients With Severe COPD Active, not recruiting NCT02972476 Phase 4 Budesonide & formoterol fumarate and Aclidinium bromide;Fluticasone 500 & salmeterol and Aclidinium bromide;Fluticasone 250 & salmeterol and Aclidinium bromide;Aclidinium bromide & formoterol fumarate
31 A Prospective, Open-label, Interventional Phase IV Study to Assess the Safety of EupentaTM Inj. {Fully Liquid Pentavalent Vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [Recombinant-deoxyribonucleic Acid])-Haemophilus Influenzae Type b Conjugate Vaccine} Not yet recruiting NCT04056728 Phase 4
32 A Phase IV, Non-Inferiority, Observer Blind, Randomized Clinical Study Comparing Safety And Immunogenicity Of DTP-HB-Hib Vaccination by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Healthy Infants In India Terminated NCT02409095 Phase 4
33 Assessment of Antibody Responses in UK Infants Given Two Doses of 10 or 13 Valent Pneumococcal Conjugate Vaccine (PCV) in Infancy and PCV13 in the Second Year of Life (Study Code: Pneumococcal in New Combinations (PINC)) Withdrawn NCT02918708 Phase 4
34 A Phase III, Double Blind, Parallel-controlled, Randomised Study to Evaluate the Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine in Healthy Children 2 Months to 5 Years of Age Unknown status NCT02560272 Phase 3
35 A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E, Against Severe Rotavirus Gastroenteritis in Infants Unknown status NCT01305109 Phase 3
36 An Open Label Trial of Azithromycin in Chronic Productive Cough Unknown status NCT02196493 Phase 3 Azithromycin
37 A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children Unknown status NCT01619462 Phase 3
38 Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection Unknown status NCT02368470 Phase 3 Gemifloxacin-based triple therapy;Standard triple therapy
39 Randomized Controlled Trial Comparing Long and Short Duration of Antibiotic Prophylaxis for Patients Undergoing Sinus Lift Surgery Unknown status NCT02764710 Phase 3 Amoxicillin-Potassium Clavulanate Combination
40 A Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen Compared to Monovalent Haemophilus Influenzae Type b (Hib) Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age. Completed NCT00345579 Phase 3
41 Assessment of the Immunogenicity and Safety of Quinvaxem Vaccine (DTwP-HepB-Hib) Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by H. Influenzae Among Healthy Vietnamese Children Completed NCT01362517 Phase 3
42 A Phase III Open Label, Multi-Center Pediatric Study in China Comparing Booster Doses of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b (Hib) Infection Completed NCT01025544 Phase 3
43 Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to Monovalent Hib Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age. Completed NCT00345683 Phase 3
44 Impact on Nasopharyngeal Carriage, Acute Otitis Media, Immunogenicity and Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Completed NCT00839254 Phase 3
45 Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease Completed NCT00861380 Phase 3
46 A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Investigate Immunogenicity and Safety of Haemophilus Influenzae Type b Vaccine in 2 - 4 Months Old Healthy Infants in China, According to the Recommended Regimen of 3 Intramuscular Doses Given One Month Apart Completed NCT00808392 Phase 3
47 A Phase III Observer Blind Single-Coordinating Center Pediatric Study in China Comparing a Booster Dose of Vaxemâ„¢ Hib to HIBERIX® When Given as Part of a Local Dosing Regimen in Infants Completed NCT01226953 Phase 3
48 A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2+1 Dose Series of Either CRM197-Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-Conjugate Haemophilus Influenzae Type b Vaccine Completed NCT02139228 Phase 3
49 A Phase III Observer-blind, Randomized, Controlled, Single-coordinating Center Study to Investigate Immunogenicity and Safety of a Monovalent Glycoprotein-conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children in China, According to the Recommended Regimen of 1 Dose Completed NCT01125527 Phase 3
50 A Multicentre, Comparative, Two-arm, Parallel-group, Double-blind, Randomized Phase III Study to Assess Immunogenicity and Safety of LBVH0101 (Haemophilus Influenzae Type b Tetanus Toxoid Conjugate Vaccine) Compared With Hiberixâ„¢ Vaccine in Healthy Infants at Two, Four and Six Months of Age Completed NCT01019772 Phase 3

Search NIH Clinical Center for Haemophilus Influenzae

Sources

Genetic Tests for Haemophilus Influenzae

About this section
Sources

Anatomical Context for Haemophilus Influenzae

About this section

MalaCards organs/tissues related to Haemophilus Influenzae:

40
Testes, Colon, Lung, Tonsil, Neutrophil, B Cells, Bone
Sources

Publications for Haemophilus Influenzae

About this section

Articles related to Haemophilus Influenzae:

(show top 50) (show all 18554)
# Title Authors PMID Year
1
Co-infection with respiratory pathogens among COVID-2019 cases. 61
32408156 2020
2
Assessment of trimethoprim-sulfamethoxazole susceptibility testing methods for fastidious Haemophilus spp. 61
31811916 2020
3
Polymorphism of ftsI gene in Haemophilus influenzae and emergence of cefotaxime resistance in two Tunisian hospitals. 61
32489667 2020
4
Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study. 61
32027810 2020
5
Seasonality of postoperative pneumonia after coronary artery bypass grafting: A national inpatient sample study. 61
32340078 2020
6
Sphingosine signaling dysfunction in airway cells as a potential contributor to progression from protracted bacterial bronchitis to bronchiectasis in children. 61
32176839 2020
7
Prevalence and clinical significance of common respiratory pathogens in the upper respiratory tract of children with community-acquired pneumonia in Zunyi, China. 61
32579285 2020
8
Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of japanese society of chemotherapy, the japanese association for infectious diseases, and the japanese society for clinical microbiology in 2016: General view of the pathogens' antibacterial susceptibility. 61
32565151 2020
9
Viral-bacterial (co-)occurrence in the upper airways and the risk of childhood pneumonia in resource-limited settings. 61
32533999 2020
10
Clinical factors influencing the performance of bacterial multiplex polymerase chain reaction in patients with community-onset pneumonia. 61
32219584 2020
11
Macrophage depletion in CCR2-/- mice delays bacterial clearance and enhances neutrophil infiltration in an acute otitis media model. 61
32572481 2020
12
The effect of pneumococcal conjugate vaccines on otitis media from 2005 to 2013 in children aged ≤5 years: a retrospective cohort study in two Swedish regions. 61
32574101 2020
13
Nontypeable Haemophilus influenzae Type IV pilus mediates augmented adherence to rhinovirus-infected human airway epithelial cells. 61
32540869 2020
14
Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets. 61
31788746 2020
15
Development of a DNA microarray assay for rapid detection of fifteen bacterial pathogens in pneumonia. 61
32576241 2020
16
Airway bacterial carriage and childhood respiratory health: a population-based prospective cohort study. 61
32524657 2020
17
Haemophilus influenzae type b and pneumococcal conjugate vaccination coverage in children aged 2-59 months in Malawi. 61
32574099 2020
18
Peptide Methionine Sulfoxide Reductase from Haemophilus influenzae Is Required for Protection against HOCl and Affects the Host Response to Infection. 61
32492342 2020
19
Haemophilus influenzae serotype a (Hia) carriage in a small Alaska community after a cluster of invasive Hia disease, 2018. 61
32531017 2020
20
Impact of routine vaccination against Haemophilus influenzae type b in The Gambia: 20 years after its introduction. 61
32509291 2020
21
Haemophilus influenzae HP1 Bacteriophage Encodes a Lytic Cassette with a Pinholin and a Signal-Arrest-Release Endolysin. 61
32512736 2020
22
Fluoroquinolone resistance in Haemophilus influenzae from nursing home residents in Taiwan: correlation of MICs and mutations in QRDRs. 61
31951091 2020
23
Control of vaccine preventable diseases in Australian infants: reviewing a decade of experience with DTPa-HBV-IPV/Hib vaccine. 61
32573398 2020
24
Infant antibody levels following 10-valent pneumococcal-protein D conjugate and DTaP-Hib vaccinations in the first year of life after maternal Tdap vaccination: An open-label, parallel, randomised controlled trial. 61
32448624 2020
25
Access, demand, and utilization of childhood immunization services: A cross-sectional household survey in Western Area Urban district, Sierra Leone, 2019. 61
32509292 2020
26
Measuring the cellular memory B cell response after vaccination in patients after allogeneic stem cell transplantation. 61
32519092 2020
27
Haemophilus spp., an emerging multidrug-resistant sexually transmitted pathogen. 61
32569798 2020
28
Rapid identification by MALDI-TOF/MS and antimicrobial disk diffusion susceptibility testing for positive blood cultures after a short incubation on the WASPLab. 61
31965365 2020
29
Antibodies against the DNABII protein integration host factor (IHF) inhibit sinus implant biofilms. 61
31314141 2020
30
Bacterial colonization of the stomach and duodenum in a Swedish population with and without proton pump inhibitor treatment. 61
32514445 2020
31
Unraveling Haemophilus influenzae virulence mechanisms enable discovery of new targets for antimicrobials and vaccines. 61
32304471 2020
32
Invasive Haemophilus influenzae type a disease: an unmet health need. 61
32531015 2020
33
Molecular epidemiology and evolution of Haemophilus influenzae. 61
31981610 2020
34
Recent trends in pediatric bacterial meningitis in Japan, 2016-2018 - S. agalactiae has been the most common pathogen. 61
32546331 2020
35
Lascufloxacin hydrochloride to treat bacterial infection. 61
32525135 2020
36
Nontypeable Haemophilus influenzae Responds to Virus-Infected Cells with a Significant Increase in Type IV Pilus Expression. 61
32461275 2020
37
10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial. 61
32448790 2020
38
Bacterial colonization dynamics associated with respiratory syncytial virus during early childhood. 61
32176838 2020
39
Analysis of Inflammatory Signaling in Human Middle Ear Cell Culture Models of Pediatric Otitis Media. 61
32433794 2020
40
An up-to-date review on bio-resource therapeutics effective against bacterial species frequently associated with chronic sinusitis and tonsillitis. 61
32368971 2020
41
Pathogen analysis of pertussis-like syndrome in children. 61
32429853 2020
42
Etiology of Pediatric Meningitis in West Africa Using Molecular Methods in the Era of Conjugate Vaccines against Pneumococcus, Meningococcus, and Haemophilus influenzae Type b. 61
32458777 2020
43
Efficacy and Safety of Revaccination against Tetanus, Diphtheria, Haemophilus influenzae Type b and Hepatitis B Virus in a Prospective Cohort of Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. 61
32428736 2020
44
Transmission of respiratory tract infections at mass gathering events. 61
32149751 2020
45
Co-infections in people with COVID-19: a systematic review and meta-analysis. 61
32473235 2020
46
Infant vaccine co-administration: review of 18 years of experience with GSK's hexavalent vaccine co-administered with routine childhood vaccines. 61
32419537 2020
47
Haemophilus influenzae type b capsular polysaccharide antibody levels in Japanese young patients with hematological malignancies and asplenia. 61
32402734 2020
48
Alterations of salivary microbial community associated with oropharyngeal and hypopharyngeal squamous cell carcinoma patients. 61
31832691 2020
49
Adrenal paracoccidioidomycosis 61
32463603 2020
50
Draft Genome Sequence of an Isolate of Nontypeable Haemophilus influenzae from an Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Tasmania. 61
32381620 2020
Sources

Variations for Haemophilus Influenzae

About this section
Sources

Expression for Haemophilus Influenzae

About this section
Search GEO for disease gene expression data for Haemophilus Influenzae.
Sources

Pathways for Haemophilus Influenzae

About this section

Pathways related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
IL-17 Family Signaling Pathways 64
Show member pathways
 12.05 TNF TLR2 CXCL8
2
Salmonella infection (KEGG) 36
12.01 TNF TLR2 CXCL8
3
Proteoglycans in cancer 36
12 VTN TNF TLR2
4
Diseases associated with the TLR signaling cascade 65
Show member pathways
 11.95 TNF TLR2 CXCL8
5
Tuberculosis 36
11.89 TNF TLR2 CLEC7A
6
Bacterial infections in CF airways 22
Show member pathways
 11.83 TNF TLR2 CXCL8
7
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.79 TNF TF CXCL8
8
Amoebiasis 36
11.51 TNF TLR2 CXCL8
9
Rheumatoid arthritis 36
11.4 TNF TLR2 CXCL8
10
Phagocytosis of Microbes 63
11.26 VTN TLR2 CLEC7A
11
Legionellosis 36
10.89 TNF TLR2 CXCL8
12
EBV LMP1 signaling 1
10.86 TNF CXCL8
13
Overview of nanoparticle effects 1
10.65 TNF CXCL8
14
Malaria 36
10.5 TNF TLR2 CXCL8
Sources

GO Terms for Haemophilus Influenzae

About this section

Cellular components related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 VTN TNF TF LTF CXCL8 CFH
2 blood microparticle GO:0072562 9.13 VTN TF CFH
3 cell surface GO:0009986 9.02 TNF TLR2 TF LTF CLEC7A

Biological processes related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.73 VTN TNF TLR2 CXCL8
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.63 TNF TLR2 LTF
3 iron ion homeostasis GO:0055072 9.57 TF LTF
4 lipopolysaccharide-mediated signaling pathway GO:0031663 9.56 TNF TLR2
5 osteoclast differentiation GO:0030316 9.55 TNF TF
6 microglial cell activation GO:0001774 9.54 TNF TLR2
7 positive regulation of interleukin-8 production GO:0032757 9.52 TNF TLR2
8 positive regulation of wound healing GO:0090303 9.51 VTN CLEC7A
9 positive regulation of receptor-mediated endocytosis GO:0048260 9.49 VTN TF
10 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.48 TNF CLEC7A
11 positive regulation of chemokine production GO:0032722 9.4 TNF TLR2
12 embryonic digestive tract development GO:0048566 9.37 TNF CXCL8
13 positive regulation of interleukin-8 secretion GO:2000484 9.32 TNF TLR2
14 positive regulation of interleukin-6 biosynthetic process GO:0045410 9.26 TNF CLEC7A
15 inflammatory response GO:0006954 9.26 TNF TLR2 CXCL8 CLEC7A
16 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.16 TNF CLEC7A
17 response to molecule of bacterial origin GO:0002237 8.62 TLR2 CXCL8

Molecular functions related to Haemophilus Influenzae according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.55 VTN TNF TLR2 LACTB CFH
2 lipopolysaccharide binding GO:0001530 9.26 TLR2 LTF
3 heparin binding GO:0008201 9.13 VTN LTF CFH
4 pattern recognition receptor activity GO:0038187 8.62 TLR2 CLEC7A
Sources

Sources for Haemophilus Influenzae

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....